However, the TMB distribution in EGFR mutant patients with NSCLC is not well demonstrated, and the effects of TMB on the outcomes of cell therapies such as CIK immunotherapy have not been explored. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.